OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide analogue sourced from bovine adrenal medulla, intended for the management of neuropathic ocular pain.